[Effects of short-term treatment of somatostatin on angiogenesis of gastric carcinoma].

Background & Objective: It is a hot spot in tumor therapies to inhibit the angiogenesis of carcinoma. Our current study was designed to investigate the inhibitory effect of somatostatin analogue on the angiogenesis of gastric carcinoma by hypodermic injection.

Methods: Twenty-five patients who have positive expression of vascular endothelial growth factor(VEGF) and somatostatin receptor 2(SSTR2)were selected by gastroscopic biopsy and immunohistochemical staining before surgical operation. After 7 days of Sandostatin administration (10 microg/kg, hypodermic injection, twice a day), the tumor extirpations were made. During the Sandostatin treatment, the serum levels of VEGF and the basic fibroblast growth factor(bFGF)were measured by enzyme-linked immunosorbant assay (ELISA) (d1,d3,d7, separately). Before and after operation,the expression levels of VEGF and bFGF were examined by Western blot analysis and the density of micro-vessels was determined by immunohistochemical staining.

Results: After a week of Sandostatin therapy,the concentration of VEGF and bFGF in serum was drastically diminished (VEGF:1.02+/-0.41 microg /L vs 1.88+/-0.87 microg/L, P< 0.05;bFGF:0.88+/-0.32 ng/L vs 2.12+/-1.06 ng/L,P< 0.05). The expression levels of VEGF(absorbance:1.306 vs 488,P< 0.01) and bFGF(absorbance:1.287 vs 512,P< 0.01) were obviously decreased after the remedy. The density of micro-vessels turn to the less, but there was no statistical difference before and after operation(P >0.05).

Conclusion: By the short-term therapy of sandostatin, the expression of VEGF and bFGF can be inhibited. There is a tendency that the serum levels of VEGF and bFGF decrease with the increase of therapy time.